Citius Oncology, Inc. (CTOR) stock
Close on Nov 11, 2026Market cap $51.60MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $51.60M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.28
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$46.06M
- EPS, diluted
- -$0.47
- Book value per share
- $0.37
- Diluted shares
- 108M
Trading
- Next earnings
- Feb 12, 2027 (estimated, before the open)
- Previous close
- $0.56
- Open
- $0.55
- Day's range
- $0.54 – $0.57
- Volume
- 45,760
- Average volume (20 days)
- 156,166
- Beta (5 years)
- 1.09
- 52-week range
- $0.49 – $1.83
- RSI (14 days)
- 37.7
- Volatility (1 year)
- 94.5%
- Relative volume
- 0.42×
- WACC
- 9.7%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CTOR | S&P 500 | Difference | CTOR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -33.9% | -2.4% | −31.5 pts | ||
| 3 months | -24.0% | -1.2% | −22.8 pts | ||
| Year to date | -44.5% | +12.3% | −56.8 pts | ||
| 1 year | -59.5% | +12.4% | −71.9 pts | ||
| 3 years | -94.9% | +78.8% | −173.7 pts | -62.9% | +21.4% |
Three years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Citius Oncology filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- News
- News
- Results
About Citius Oncology
Pharmaceutical Preparations
Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies. Its primary approved product is LYMPHIR (denileukin diftitox-cdxl), an engineered interleukin-2 diphtheria toxin fusion protein. The medication is designed for adult patients suffering from persistent or recurrent cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. LYMPHIR operates through a dual mechanism that delivers cytotoxic diphtheria toxin directly to cells expressing interleukin-2 receptors while simultaneously depleting immunosuppressive regulatory T cells.
Company profile, executives and historyCitius Oncology stock: common questions
What is Citius Oncology's stock price?
CTOR closed at $0.55 on Nov 11, 2026, down 1.39% on the day. Over the past 52 weeks it traded between $0.49 and $1.83.
What is Citius Oncology's market cap?
Citius Oncology was worth $51.60M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CTOR's P/E ratio?
Citius Oncology lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.47), so it has no meaningful P/E ratio.
Does Citius Oncology pay a dividend?
No. Citius Oncology has not paid a cash dividend over the last twelve months.
When does Citius Oncology report earnings next?
Citius Oncology is expected to report Q1 FY2027 results on Feb 12, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CTOR stock performed over the past year?
Including dividends, CTOR returned -59.5% over the past year, against +12.4% for the S&P 500.
How many CTOR shares are sold short?
0M shares were sold short at the latest FINRA report, 0.97% of the float, or 1.2 days of average trading volume.
Who are Citius Oncology's competitors?
Companies most similar to Citius Oncology by business, industry and size include CTXR, CLRB, ADCT, KURA, PHIO.
See a number that looks wrong?